Canada Markets open in 2 hrs 34 mins
  • S&P/TSX

    21,537.45
    +179.89 (+0.84%)
     
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • DOW

    35,911.81
    -201.79 (-0.56%)
     
  • CAD/USD

    0.8002
    +0.0012 (+0.1472%)
     
  • CRUDE OIL

    85.14
    +1.32 (+1.57%)
     
  • BTC-CAD

    52,276.31
    -1,494.69 (-2.78%)
     
  • CMC Crypto 200

    1,001.36
    -24.37 (-2.38%)
     
  • GOLD FUTURES

    1,813.40
    -3.10 (-0.17%)
     
  • RUSSELL 2000

    2,162.46
    +3.02 (+0.14%)
     
  • 10-Yr Bond

    1.7720
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,327.00
    -268.75 (-1.72%)
     
  • VOLATILITY

    21.63
    +1.32 (+6.50%)
     
  • FTSE

    7,565.09
    -46.14 (-0.61%)
     
  • NIKKEI 225

    28,257.25
    -76.27 (-0.27%)
     
  • CAD/EUR

    0.7023
    +0.0022 (+0.31%)
     

Alzheimer's Disease Treatment Global Market Research Report 2021 Featuring Allergan, Eisai, Novartis, Pfizer, Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche - ResearchAndMarkets.com

·4 min read

DUBLIN, December 08, 2021--(BUSINESS WIRE)--The "Alzheimer's Disease Treatment Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

The global alzheimer's disease treatment market is expected to grow from $3.43 billion in 2020 to $3.76 billion in 2021 at a compound annual growth rate (CAGR) of 9.6%. The market is expected to reach $5.91 billion in 2025 at a CAGR of 12%.

Major players in the Alzheimer's disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd.

The global Alzheimer's disease treatment market consists of sales of drugs used to treat Alzheimer's disease. Alzheimer's disease is a progressive neurological disorder causing degeneration of brain cells, resulting in dementia (a condition that causes a decline in thinking, behavioural and social skills). The progression of this disease causes severe memory impairment and the person may lose the ability to carry out everyday tasks.

The Alzheimer's disease treatment market covered in this report is segmented by drug class into cholinergic, memantine, combined drug, AChE inhibitors, immunoglobulins and by drug type into cholinesterase inhibitors, NMDA receptor antagonists.

Lack of techniques for diagnosing Alzheimer's disease (AD) is expected to limit the growth of the global Alzheimer's disease treatment market. There is no definitive blood test, brain scan, or physical exam to diagnose AD, and so many conditions can produce symptoms like dementia, which is the primary clinical symptom of AD, making the diagnosis complicated.

The lack of a single test for diagnosis, specialists such as neurologists, neuropsychologists, geriatricians and geriatric psychiatrists use a variety of approaches for diagnosis to confirm dementia, but it is still difficult to find the cause resulting in late diagnosis. Lack of proper and quick diagnosis for AD hampers the market growth as it leads to a reduced number of diagnosed cases and thereby reduces the consumption of AD drugs.

The increasing cases of Alzheimer's is a major factor contributing to the growth of the Alzheimer's treatment market. Alzheimer's is the most common type of dementia. The USA Alzheimer's Association expects that all the states in the US are projected to face a rise of at least 14% in the number of Alzheimer's people between 2017 and 2025 due to the increase in the geriatric population. At the global level, the estimated new cases of Alzheimer's is expected to grow by 35% to 615,000 by 2030, and by 110% to 959,000 by 2050. Therefore, the increasing prevalence of Alzheimer's disease is expected to drive the growth of the global Alzheimer's disease treatment market.

Increasing R&D investments and collaborations due to the emerging technologies for the treatment is a key trend in Alzheimer's disease (AD) treatment market. The Alzheimer's Association is assisting with funds to researchers in search of innovative therapeutic approaches and seeks more government funding for Alzheimer's studies.

Key Topics Covered:

1. Executive Summary

2. Alzheimer's Disease Treatment Market Characteristics

3. Alzheimer's Disease Treatment Market Trends and Strategies

4. Impact Of COVID-19 On Alzheimer's Disease Treatment

5. Alzheimer's Disease Treatment Market Size and Growth

5.1. Global Alzheimer's Disease Treatment Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. Global Alzheimer's Disease Treatment Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. Alzheimer's Disease Treatment Market Segmentation

6.1. Global Alzheimer's Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Cholinergic

  • Memantine

  • Combined Drug

  • AChE inhibitors

  • Immunoglobulins

6.2. Global Alzheimer's Disease Treatment Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Cholinesterase Inhibitors

  • NMDA Receptor Antagonists

6.3. Global Alzheimer's Disease Treatment Market, Segmentation by therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Cholinesterase Inhibitors

  • NMDA Receptor Antagonists

  • Other therapeutics

7. Alzheimer's Disease Treatment Market Regional and Country Analysis

7.1. Global Alzheimer's Disease Treatment Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Alzheimer's Disease Treatment Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

  • Allergan

  • Eisai Co. Ltd.

  • Novartis AG

  • Pfizer Inc.

  • Merz Pharma

  • H. Lundbeck A/S Biogen

  • AstraZeneca

  • F. Hoffmann-La Roche Ltd

  • Eli Lilly and Company

  • Teva Pharmaceutical Industries Ltd.

  • ONO Pharmaceutical Co. Ltd.

  • VTV Therapeutics

  • TauRx

  • AC Immune

  • AB Science

  • AbbVie Inc.

  • Bristol-Myers Squibb Company

  • Takeda Pharmaceutical Company Limited.

  • Bayer AG

  • Amgen

  • UCB

  • Forest Laboratories

  • Merck Sharp & Dohme Corp.

  • Biogen

For more information about this report visit https://www.researchandmarkets.com/r/m0fzzi

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005828/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting